SAC Capital Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

SAC Capital Advisors’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-400,000	Closed	-$8.14M	–	1234
2014 Q1	$8.14M	Sell	400,000 -311,162	-44%	-$7.55M	0.04%	451
2013 Q4	$13.9M	Buy	711,162 +236,062	+50%	+$6.3M	0.08%	298
2013 Q3	$21.5M	Buy	475,100 +309,177	+186%	+$10.1M	0.12%	226
2013 Q2	$3.96M	Buy	+165,923	New	+$2.64M	0.02%	579

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

SAC Capital Advisors's STML Position: Q2 2014 in Review

SAC Capital Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2014, closing a stake of 400,000 shares — an estimated $8.14M sold.

SAC Capital Advisors first reported a position in STML in Q2 2013 and held it in 4 quarters. The position peaked at $21.5M in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q2 2014.

SAC Capital Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 400,000 Stemline Therapeutics, Inc. shares in Q2 2014, an estimated $8.14M.
SAC Capital Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's Stemline Therapeutics, Inc. position peaked at $21.5M in Q3 2013.
61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.